Portfolio auf einen Blick
Wertschriften per 30. Juni 2021
| Gesellschaft | 
 | Anzahl Wert- schriften | 
 | Veränderung seit 31.12.2020 | 
 | Währung | 
 | Aktienkurs | 
 | Kurswert in Mio. CHF | 
 | In % der Wert- schriften | 
 | In % des Eigen- kapitals | 
 | In % der Gesell- schaft | 
| Moderna | 
 | 2 450 000 | 
 | (404 963) | 
 | USD | 
 | 234.98 | 
 | 532.5 | 
 | 12.2% | 
 | 13.2% | 
 | 0.6% | 
| Ionis Pharmaceuticals | 
 | 9 112 973 | 
 | 892 973 | 
 | USD | 
 | 39.89 | 
 | 336.3 | 
 | 7.7% | 
 | 8.3% | 
 | 6.5% | 
| Argenx SE | 
 | 955 538 | 
 | 34 206 | 
 | USD | 
 | 301.07 | 
 | 266.1 | 
 | 6.1% | 
 | 6.6% | 
 | 1.9% | 
| Neurocrine Biosciences | 
 | 2 915 400 | 
 | (119 600) | 
 | USD | 
 | 97.32 | 
 | 262.4 | 
 | 6.0% | 
 | 6.5% | 
 | 3.1% | 
| Incyte | 
 | 2 897 000 | 
 | (3 000) | 
 | USD | 
 | 84.13 | 
 | 225.4 | 
 | 5.2% | 
 | 5.6% | 
 | 1.3% | 
| Agios Pharmaceuticals | 
 | 4 304 992 | 
 | 146 090 | 
 | USD | 
 | 55.11 | 
 | 219.5 | 
 | 5.0% | 
 | 5.4% | 
 | 7.0% | 
| 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
| Fate Therapeutics | 
 | 2 546 336 | 
 | 516 336 | 
 | USD | 
 | 86.79 | 
 | 204.4 | 
 | 4.7% | 
 | 5.1% | 
 | 2.7% | 
| Vertex Pharmaceuticals | 
 | 1 050 000 | 
 | 150 000 | 
 | USD | 
 | 201.63 | 
 | 195.8 | 
 | 4.5% | 
 | 4.8% | 
 | 0.4% | 
| Alnylam Pharmaceuticals | 
 | 1 110 000 | 
 | (45 000) | 
 | USD | 
 | 169.52 | 
 | 174.1 | 
 | 4.0% | 
 | 4.3% | 
 | 0.9% | 
| Biogen | 
 | 500 000 | 
 | (37 000) | 
 | USD | 
 | 346.27 | 
 | 160.1 | 
 | 3.7% | 
 | 4.0% | 
 | 0.3% | 
| Macrogenics | 
 | 6 275 564 | 
 | 1 460 000 | 
 | USD | 
 | 26.86 | 
 | 155.9 | 
 | 3.6% | 
 | 3.9% | 
 | 10.5% | 
| Arvinas | 
 | 2 176 903 | 
 | – | 
 | USD | 
 | 77.00 | 
 | 155.0 | 
 | 3.6% | 
 | 3.8% | 
 | 4.4% | 
| Crispr Therapeutics | 
 | 949 584 | 
 | 48 700 | 
 | USD | 
 | 161.89 | 
 | 142.2 | 
 | 3.3% | 
 | 3.5% | 
 | 1.3% | 
| Intra-Cellular Therapies | 
 | 3 488 419 | 
 | (50 000) | 
 | USD | 
 | 40.82 | 
 | 131.7 | 
 | 3.0% | 
 | 3.3% | 
 | 4.3% | 
| Radius Health | 
 | 7 455 714 | 
 | – | 
 | USD | 
 | 18.24 | 
 | 125.8 | 
 | 2.9% | 
 | 3.1% | 
 | 15.8% | 
| Sage Therapeutics | 
 | 2 325 104 | 
 | 785 000 | 
 | USD | 
 | 56.81 | 
 | 122.2 | 
 | 2.8% | 
 | 3.0% | 
 | 4.0% | 
| Myovant Sciences | 
 | 5 222 039 | 
 | 465 000 | 
 | USD | 
 | 22.77 | 
 | 110.0 | 
 | 2.5% | 
 | 2.7% | 
 | 5.7% | 
| Relay Therapeutics | 
 | 2 620 962 | 
 | 1 211 605 | 
 | USD | 
 | 36.59 | 
 | 88.7 | 
 | 2.0% | 
 | 2.2% | 
 | 2.8% | 
| Esperion Therapeutics | 
 | 4 477 964 | 
 | 530 000 | 
 | USD | 
 | 21.15 | 
 | 87.6 | 
 | 2.0% | 
 | 2.2% | 
 | 15.9% | 
| Beam Therapeutics | 
 | 606 821 | 
 | 210 000 | 
 | USD | 
 | 128.71 | 
 | 72.2 | 
 | 1.7% | 
 | 1.8% | 
 | 1.0% | 
| Molecular Templates | 
 | 9 542 621 | 
 | 3 162 290 | 
 | USD | 
 | 7.82 | 
 | 69.0 | 
 | 1.6% | 
 | 1.7% | 
 | 17.0% | 
| Essa Pharma | 
 | 2 440 814 | 
 | 2 440 814 | 
 | USD | 
 | 28.57 | 
 | 64.5 | 
 | 1.5% | 
 | 1.6% | 
 | 6.0% | 
| Generation Bio Co. | 
 | 2 453 180 | 
 | 120 000 | 
 | USD | 
 | 26.90 | 
 | 61.0 | 
 | 1.4% | 
 | 1.5% | 
 | 4.3% | 
| Scholar Rock Holding | 
 | 2 275 125 | 
 | 19 474 | 
 | USD | 
 | 28.90 | 
 | 60.8 | 
 | 1.4% | 
 | 1.5% | 
 | 6.6% | 
| Halozyme Therapeutics | 
 | 1 331 966 | 
 | (2 638 034) | 
 | USD | 
 | 45.41 | 
 | 55.9 | 
 | 1.3% | 
 | 1.4% | 
 | 0.9% | 
| Revolution Medicines | 
 | 1 805 105 | 
 | 1 805 105 | 
 | USD | 
 | 31.74 | 
 | 53.0 | 
 | 1.2% | 
 | 1.3% | 
 | 2.5% | 
| Exelixis | 
 | 2 835 000 | 
 | – | 
 | USD | 
 | 18.22 | 
 | 47.8 | 
 | 1.1% | 
 | 1.2% | 
 | 0.9% | 
| Nektar Therapeutics | 
 | 2 620 676 | 
 | – | 
 | USD | 
 | 17.16 | 
 | 41.6 | 
 | 1.0% | 
 | 1.0% | 
 | 1.4% | 
| Black Diamond Therapeutics | 
 | 3 440 000 | 
 | 2 050 000 | 
 | USD | 
 | 12.19 | 
 | 38.8 | 
 | 0.9% | 
 | 1.0% | 
 | 9.5% | 
| Mersana Therapeutics | 
 | 2 860 000 | 
 | 975 000 | 
 | USD | 
 | 13.58 | 
 | 35.9 | 
 | 0.8% | 
 | 0.9% | 
 | 4.1% | 
| Kezar Life Sciences | 
 | 4 533 148 | 
 | – | 
 | USD | 
 | 5.43 | 
 | 22.8 | 
 | 0.5% | 
 | 0.6% | 
 | 9.4% | 
| Wave Life Sciences | 
 | 2 602 858 | 
 | – | 
 | USD | 
 | 6.66 | 
 | 16.0 | 
 | 0.4% | 
 | 0.4% | 
 | 5.2% | 
| Homology Medicines | 
 | 1 737 122 | 
 | – | 
 | USD | 
 | 7.27 | 
 | 11.7 | 
 | 0.3% | 
 | 0.3% | 
 | 3.0% | 
| 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
| Alder Biopharmaceuticals – Contingent Value Right | 
 | 2 766 008 | 
 | – | 
 | USD | 
 | 0.88 | 
 | 2.3 | 
 | 0.1% | 
 | 0.1% | 
 | 
 | 
| 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
| Total Wertschriften | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 4 349.3 | 
 | 100.0% | 
 | 107.5% | 
 | 
 | 
| 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
| Übrige Aktiven | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 7.8 | 
 | 
 | 
 | 0.2% | 
 | 
 | 
| Übrige Verbindlichkeiten | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | (310.1) | 
 | 
 | 
 | (7.7%) | 
 | 
 | 
| Innerer Wert | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 4 047.0 | 
 | 
 | 
 | 100.0% | 
 | 
 | 
| 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
| BB Biotech Namenaktien 1) | 
 | – | 
 | (114 662) | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
1 Entspricht der Summe aller gehaltenen Aktien inkl. 2. Handelslinie
Wechselkurs per 30.06.2021: USD/CHF: 0.9250